TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29236165
Drug: Dose 0
Normalized name: Femhrt Low Dose 0.5/2.5 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 0 Control (D0C)
Study: 17385190
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group therapy (SEGT) plus three classes of relaxation therapy
Study: 17385190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving three classes of relaxation therapy
Study: 16350553
Drug: 140 ml@4ml/s
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 ml@4ml/s
Study: 16350553
Drug: 140 ml
Normalized name: syringe, disposable, 140 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 ml = 60 ml@5ml/s + 80 ml@3ml/s
Study: 16350553
Drug: 100 ml@4ml/s
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml@4ml/s
Study: 11408506
Drug: VA chemotherapy
Normalized name: VP/VA COPOLYMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA chemotherapy
Study: 9723149
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of referral strategies (fixed appointment, involvement of the family, presence of the aftercare person, motivational counselling)
Study: 7994812
Drug: Trapidil 100
Normalized name: trapidil
DrugBank: Trapidil (DB09283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil 100 mg TID
Study: 7994812
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg TID
Study: 31022555
Drug: Literacy-adapted group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Literacy-adapted group cognitive-behavioral therapy (CBT)
Study: 20383545
Drug: 10% casein
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% casein phosphopeptide‐amorphous calcium phosphate (CPP‐ACP) applied once daily (Tooth Mousse, GC Europe)
Study: 19468787
Drug: Pentoxyphylline (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxyphylline (800 mg daily) and vitamin E (800 UI daily)
Study: 15841813
Drug: Resting whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resting whole salivary secretion rate < or =0.1 mL/min
Study: 15841813
Drug: Stimulated whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulated whole salivary flow rates <0.7 mL/min
Study: 8956556
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment of variceal bleeding
Study: 2581467
Drug: Cimetidine 100
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 100 mg orally once a day for 4 weeks
Study: 30958069
Drug: 12 µg
Normalized name: penicillin G 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 µg of formoterol (FOR)
Study: 30958069
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg of salmeterol (SAL)
Study: 30139419
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine supplementation (400 mg per dancer, 6.3 mg/kg, range: 4.9 to 8.6 mg/kg)
Study: 19056575
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (1 mg . kg(‐1) . d(‐1)) from 4 to 9 months
Study: 19056575
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (1 mg . kg(‐1) . d(‐1)) from 6 to 9 months
Study: 17634458
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol 400 mg subcutaneously at weeks 0, 2, and 4, then every 4 weeks
Study: 12847475
Drug: Disodium cromoglycate
Normalized name: Disodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium cromoglycate (5 mg qid)
Study: 10597739
Drug: Accelerated weekly
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated weekly schedule (AWS) of cisplatin (100 mg/m2 every week for two triplets of three cycles separated by a 5-week interval)
Study: 10597739
Drug: Conventional 3-weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional 3-weekly schedule (CTWS) of cisplatin (100 mg/m2 every 3 weeks for six cycles)
Study: 7036726
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg per day
Study: 7036726
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg per day
Study: 6355242
Drug: Diltiazem 360
Normalized name: dilTIAZem 360 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 360 mg per day
Study: 6355242
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose diltiazem
Study: 30151229
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (+50 g protein per day)
Study: 24331630
Drug: Enhanced nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced nutritional therapy (n = 25)
Study: 14557756
Drug: FTY720 (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTY720 (0.125, 0.25, 0.5, 1.0, 2.5, or 5.0 mg/day)
Study: 8774628
Drug: Antioxidant regimen
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant regimen (vitamins E, C and N‐acetylcysteine) in chemotherapy group
Study: 8774628
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in chemotherapy group
Study: 31168845
Drug: Curcuminoids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids plus piperine (500 mg curcuminoids and 5 mg piperine daily)
Study: 2527729
Drug: Seven low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Seven low-dose oral contraceptive preparations (monophasic and triphasic levonorgestrel, monophasic and biphasic desogestrel, monophasic norethisterone, monophasic cyproterone acetate, triphasic gestodene)
Study: 2527729
Drug: Seven low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Seven low-dose oral contraceptive preparations
Study: 326635
Drug: Antibiotics effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics effective against obligate anaerobes
Study: 31587982
Drug: Intravenous Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Dexamethasone (DEX) 0.15 mg/kg
Study: 31036337
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment consisting of a slow infusion of 20 mg/kg ferric carboxymaltose, 40,000 U subcutaneous erythropoietin alpha, 1 mg subcutaneous vitamin B12, and 5 mg oral folic acid.
Study: 25172229
Drug: Topical petrolatum
Normalized name: petrolatum Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical petrolatum gel
Study: 25172229
Drug: Topical silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical silver sulfadiazine with gauze dressings
Study: 21455591
Drug: Augmentation mammoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation mammoplasty with mastopexy
Study: 19128802
Drug: Verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (240 mg oid) for 6 months
Study: 19128802
Drug: Trandolapril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (4 mg oid) for 6 months
Study: 19128802
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of verapamil and trandolapril for additional 6 months
Study: 11167209
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of elemental iron a day for the first two months after childbirth
Study: 11167209
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of elemental iron + 0.35 mg of folic acid a day for the first two months after childbirth
Study: 7889813
Drug: Take-home methadone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home methadone doses following each therapy session (Study 1)
Study: 7889813
Drug: Take-home methadone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home methadone doses earned following each therapy session attended (Study 2)
Study: 7889813
Drug: Take-home methadone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home methadone doses earned following attendance to two consecutive sessions (Study 2)
Study: 7889813
Drug: Take-home methadone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home methadone doses (both studies)
Study: 3608630
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative application of an antibiotic with a high biliary elimination rate (ceftriaxone or apalcillin)
Study: 3608630
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group without prophylactic antibiotic application
Study: 29112001
Drug: Risperidone ISM
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone ISM 75 mg intramuscular injections every 4 weeks
Study: 24587337
Drug: WGED (wholegrain
Approvals — FDA: no, EMA: no, PMDA: no
Description: WGED (wholegrain and low postprandial insulin response grain products)
Study: 22992702
Drug: Continuous rhLH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous rhLH infusion
Study: 17883958
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL YZH oral liquid, 3 times daily for 14 d
Study: 15749498
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (LMWH) plus low-dose aspirin (LDA)
Study: 15749498
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) plus low-dose aspirin (LDA)
Study: 7760409
Drug: Protocol resuscitation
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol resuscitation goals (CI > or = 4.5 L/min/m2, DO2I > or = 670 mL/min/m2, VO2I > or = 166 mL/min/m2)
Study: 357455
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sublingual pentrinitrol
Study: 27838874
Drug: red yeast
Normalized name: red yeast
Approvals — FDA: no, EMA: no, PMDA: no
Description: red yeast rice + L. casei
Study: 17280744
Drug: Tetanus toxoid
Normalized name: Tetanus Toxoid
DrugBank: Clostridium tetani toxoid antigen (formaldehyde inactivated) (DB10583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus toxoid vaccine (0.5 ml)
Study: 11467632
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg administered nasogastrically in apple juice
Study: 11467632
Drug: Pantoprazole, 40
Normalized name: Pantoprazole, 40 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, 40 mg administered intravenously
Study: 7912877
Drug: Midazolam 0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.08 mg kg‐1 i.m. 60 min and fentanyl 1.5 micrograms kg‐1 i.v. 2 min before induction (MF group)
Study: 2681556
Drug: High-dose metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose metoclopramide (1 mg/kg x 4) and methylprednisolone (treatment A)
Study: 2681556
Drug: Metoclopramide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (3 mg/kg x 2) combined with dexamethasone and diphenhydramine (treatment B)
Study: 30409925
Drug: High SPF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High SPF sunscreen (SPF 50+, PA++++) applied once daily after bath or every 4 hours for outdoor exposure >4 hours for 3 months.
Study: 22015190
Drug: Shuxuetong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuxuetong injection and Tuina
Study: 15316798
Drug: TPM 100
Normalized name: TPM
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TPM 100 mg/d
Study: 15316798
Drug: PROP 160
Normalized name: PROPYLENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROP 160 mg/d (active control)
Study: 15316798
Drug: TPM 200
Normalized name: TPM
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TPM 200 mg/d
Study: 9431627
Drug: Full intervention
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full intervention (combination of clinical and occupational intervention)
Study: 7993832
Drug: i.m. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. dexamethasone and oral metoclopramide for delayed emesis
Study: 31784906
Drug: Electrical muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical muscle stimulation in combination with heat (EMS/H)
Study: 31347643
Drug: Fresh turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh turmeric meal (400 mg curcumin)
Study: 31347643
Drug: Turmeric powder
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric powder meal (400 mg curcumin)
Study: 31347643
Drug: Curcumin powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin powder meal (400 mg curcumin)
Study: 23403817
Drug: Ridaforolimus 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridaforolimus 12.5mg intravenously once daily for 5 consecutive days every 2 weeks in a 4-week cycle
Study: 21138476
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg/day, 2 hr before bedtime) for 2 months
Study: 17313006
Drug: Routine medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medicine (prednisone, dibazol, vitamin B complex, and Qianzheng Powder), once each day for 10 days (2 courses total).
Study: 11471645
Drug: 15% alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% alkaline EDTA solution
Study: 11471645
Drug: 15% acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% acid EDTA solution
Study: 11471645
Drug: 25% alkaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% alkaline EDTA solution
Study: 8095779
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg guanabenz
Study: 8095779
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg guanabenz
Study: 30113724
Drug: BI 655064
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 655064 (240 mg)
Study: 31996209
Drug: Group antenatal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group antenatal care (G-ANC) in Nigeria
Study: 31996209
Drug: Group antenatal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group antenatal care (G-ANC) in Kenya
Study: 29538635
Drug: Acetaminophen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1 g 6-hourly for 72 hours)
Study: 29538635
Drug: No acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: No acetaminophen (control group)
Study: 26977740
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) applied intraorally with GaAlAs diode laser (wavelength, 810 nm; continuous mode, output power 0.3 W; 180 sec, 4 J/cm(2))
Study: 11014720
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg intravenously once daily)
Study: 1595913
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine and bretylium 1.5 mg/kg
Study: 1595913
Drug: bretylium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: bretylium administration
Study: 1595913
Drug: control treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: control treatments
Study: 6151958
Drug: Alprazolam (2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (2.7 mg mean final dose)
Study: 6151958
Drug: Doxepin (137.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (137.5 mg mean final dose)
Study: 27001189
Drug: Waon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waon therapy (once daily for 10 days, far infrared-ray dry sauna at 60℃ for 15 min, followed by 30 min bed rest covered with a blanket)
Study: 27001189
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard medical therapy)
Study: 25064777
Drug: Mirror therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror therapy (MT) combined with conventional occupational therapy, physical therapy, and speech therapy for 5 d/wk, 6 h/d, over 3 weeks
Study: 25064777
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy without MT
Study: 22194183
Drug: Citalopram 20
Normalized name: citalopram 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 20 mg daily (SSRI)
Study: 22194183
Drug: Reboxetine 4
Normalized name: reboxetine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine 4 mg twice daily (NARI)
Study: 6244198
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of 0.1% hydrocortisone 17‐butyrate ointment weekly for 4 weeks
Study: 6244198
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of 1% hydrocortisone ointment weekly for 4 weeks
Study: 6244198
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of hydrocortisone 17‐butyrate weekly for 4 weeks
Study: 6244198
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g of hydrocortisone weekly for 4 weeks
Study: 31121035
Drug: ChemoRT‐GS (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChemoRT‐GS (combination therapy gene signature)
Study: 28335622
Drug: Antidepressant Medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant Medication
Study: 25500320
Drug: Group Rational
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Rational Emotive Behavior Therapy (REBT)/CBT
Study: 25500320
Drug: Group REBT/CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group REBT/CBT plus pharmacotherapy
Study: 21378174
Drug: Diazoxide (6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (6.0 mg/kg)
Study: 10578225
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/daily) + Hydrochlorothiazide (25 mg/daily)
Study: 10578225
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/daily) + Indapamide (2.5 mg/daily)
Study: 10578225
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/daily)
Study: 10578225
Drug: Hydrochlorothiazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (25 mg/daily)
Study: 10578225
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg/daily)
Study: 10578225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P + HCT
Study: 10578225
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of P + IND
Study: 7788038
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg sustained-release isosorbide-5-nitrate
Study: 2195346
Drug: Prednisone for
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone for 6 weeks followed by 5 million units of recombinant interferon alfa‐2b daily for 16 weeks
Study: 849691
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with BCG and chemotherapy
Study: 28391289
Drug: Web-delivered sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-delivered sleep intervention (sleep-hygiene education, stimulus control, and cognitive behavioral therapy)
Study: 21454798
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 and 300 mg once daily)
Study: 17988832
Drug: GCBT+EX (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCBT+EX (Group Cognitive Behavioral Therapy + Exercise)
Study: 17988832
Drug: GCBT+ED (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCBT+ED (Group Cognitive Behavioral Therapy + Education)
Study: 8836985
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg/day) for 8 weeks
Study: 794661
Drug: Aminophylline (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (250 mg)
Study: 30770432
Drug: Preferred algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred algorithm requiring ≥3 MS-related claims from any combination of inpatient, outpatient, or DMT claims within a 1-year time period.
Study: 22373589
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S + S: normal saline 0.15 ml/kg + normal saline 0.06 ml/kg
Study: 22373589
Drug: Group S
Normalized name: Blood group substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group S + M: normal saline 0.15 ml/kg + midazolam 0.06 mg/kg
Study: 22373589
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D + S: dexmedetomidine 0.6 μg/kg + normal saline 0.06 ml/kg
Study: 22373589
Drug: Group D
Normalized name: Prostaglandin group D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group D + M: dexmedetomidine 0.6 μg/kg + midazolam 0.06 mg/kg
Study: 20833658
Drug: Clonidine-diuretics association
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine-diuretics association